Q-Bank Breakdown: HIV lifecycle & drugs — Why Every Answer Choice Matters

You’re staring at an HIV pharmacology question thinking, “I know the drugs… so why do these answer choices all feel plausible?” That’s exactly the point: HIV questions are really lifecycle questions disguised as pharm. If you can map each drug class to a specific step (and remember the classic toxicities), you can turn every distractor into a quick elimination.

Tag: Microbiology > Virology

---

The Clinical Vignette (Q-bank style)

A 29-year-old man with newly diagnosed HIV is started on antiretroviral therapy. His baseline labs show HIV RNA 180,000 copies/mL and CD4 count 240/µL. Two months later, his viral load has dropped significantly. He returns with new onset yellowing of the eyes but no abdominal pain. Labs show indirect hyperbilirubinemia with normal AST/ALT. The team reassures him this is a benign medication effect.

Which medication is most likely responsible?

A. Efavirenz
B. Raltegravir
C. Atazanavir
D. Zidovudine
E. Maraviroc

---

Step 1/2 Framework: HIV Lifecycle in One Mental Picture

HIV is an enveloped, +ssRNA retrovirus that carries reverse transcriptase, integrase, and protease.

Key steps (and the drug hooks)

1. Attachment/Entry

   • gp120 binds CD4 + co-receptor CCR5 (early) or CXCR4 (late)
   • Fusion via gp41
   • Drugs: Maraviroc (CCR5 antagonist), Enfuvirtide (gp41 fusion inhibitor)

2. Reverse transcription (RNA → DNA)

   • Drug targets: NRTIs, NNRTIs

3. Integration into host genome

   • Drug targets: Integrase inhibitors (e.g., raltegravir, dolutegravir, bictegravir)

4. Transcription/translation → polyproteins

   • (host machinery)

5. Assembly & budding

6. Maturation

   • HIV protease cleaves polyproteins into functional proteins
   • Drug targets: Protease inhibitors (e.g., atazanavir, darunavir)

---

The Correct Answer: C. Atazanavir

Why it’s correct

Atazanavir is a protease inhibitor (PI). A classic PI-associated vignette is:

• Indirect hyperbilirubinemia (often with scleral icterus)
• Normal transaminases
• Benign, due to UGT1A1 inhibition (similar mechanism vibe as Gilbert syndrome)

So the clue combo—scleral icterus + indirect bilirubin + normal AST/ALT—is basically a fingerprint for atazanavir (and sometimes indinavir), especially when the question stresses “reassure him.”

High-yield PI facts

• Mechanism: inhibits HIV protease → prevents cleavage of gag-pol polyprotein → immature, noninfectious virions
• Class toxicities (remember “HIV gives you metabolic syndrome”):
  • Hyperglycemia/insulin resistance
  • Hyperlipidemia
  • Lipodystrophy
• Drug interactions: many PIs inhibit CYP3A4 (pharm loves to test)

---

Why Each Distractor Is Wrong (and what it’s trying to test)

A. Efavirenz (NNRTI)

What it targets: reverse transcriptase (noncompetitive)

How to recognize it:

• Neuropsych effects: vivid dreams, dizziness, insomnia, mood changes
• Often tested with “weird dreams” or CNS symptoms after starting ART

Why it’s wrong here:

• Efavirenz doesn’t cause isolated indirect hyperbilirubinemia with normal AST/ALT.
• Hepatotoxicity can occur with multiple ARTs, but the question’s “benign scleral icterus” clue is much more PI/atazanavir.

Extra high-yield association

• NNRTIs: Nevirapine is more classically associated with severe hepatotoxicity and rash (including SJS/TEN).

---

B. Raltegravir (Integrase inhibitor)

What it targets: integration of viral DNA into host genome

How to recognize it:

• Generally well-tolerated
• Can cause increased CK, myalgias; rare rhabdomyolysis
• Also think: weight gain is sometimes discussed clinically, but USMLE tends to keep it simple.

Why it’s wrong here:

• Not linked to isolated indirect hyperbilirubinemia + scleral icterus.
• If they wanted integrase inhibitor toxicity, they’d hint muscle pain and elevated CK.

---

D. Zidovudine (NRTI)

What it targets: reverse transcriptase (competitive inhibition; chain termination)

How to recognize it:

• Classic NRTI adverse effects include mitochondrial toxicity
• Zidovudine specifically: bone marrow suppression → anemia, neutropenia
• Also: myopathy

Why it’s wrong here:

• The vignette gives a bilirubin pattern consistent with UGT inhibition, not marrow failure.
• Zidovudine questions usually feature:
  • Fatigue/pallor
  • Macrocytic anemia
  • Neutropenia
  • Elevated lactate (in broader NRTI mitochondrial toxicity vignettes)

---

E. Maraviroc (CCR5 antagonist)

What it targets: entry—blocks CCR5, preventing gp120 interaction

How to recognize it:

• Must have CCR5-tropic virus (requires tropism testing)
• Adverse effects can include hepatotoxicity (sometimes with systemic allergic features)

Why it’s wrong here:

• The patient has normal AST/ALT and isolated indirect hyperbilirubinemia—more consistent with atazanavir’s UGT1A1 inhibition than hepatocellular injury.

High-yield nuance

• CCR5 vs CXCR4: early infection is often CCR5-tropic; later disease may shift toward CXCR4-tropism.

---

The “Every Answer Choice Matters” Table

---

Rapid-Fire High-Yield HIV Drug Associations (USMLE Favorites)

Reverse transcriptase inhibitors

• NRTIs (e.g., tenofovir, emtricitabine, abacavir, zidovudine)
  • Mitochondrial toxicity → lactic acidosis, hepatic steatosis, pancreatitis, peripheral neuropathy (varies by agent)
  • Abacavir: HLA-B*57:01 hypersensitivity
  • Tenofovir: nephrotoxicity, decreased bone mineral density
• NNRTIs (e.g., efavirenz, nevirapine, rilpivirine)
  • Rash, hepatotoxicity; efavirenz → CNS effects

Integrase inhibitors (INSTIs)

• Raltegravir, dolutegravir, bictegravir
  • Generally well tolerated; possible ↑CK/myalgias

Protease inhibitors

• Atazanavir, darunavir, ritonavir (booster)
  • Metabolic syndrome-like effects
  • Atazanavir: indirect hyperbilirubinemia (UGT1A1 inhibition)

Entry inhibitors

• Maraviroc: CCR5 antagonist (tropism testing)
• Enfuvirtide: gp41 fusion inhibitor (injection site reactions)

---

Takeaway: How to Win These Questions Fast

1. Translate the symptom into a lab pattern (here: indirect hyperbilirubinemia with normal AST/ALT).
2. Map the pattern to a drug signature (atazanavir → UGT1A1 inhibition).
3. Use lifecycle mapping to dispose of distractors quickly (entry vs RT vs integrase vs protease).
4. Remember: USMLE loves mechanism + one signature toxicity per class.